Maplirpacept
Based on 1 Customer Validation
Maplirpacept (TTI-622; PF-07901801) is a fusion protein consisting of the CD47-binding domain of human SIRPα linked to the Fc region of human IgG4. Maplirpacept enhances phagocytosis by blocking CD47.
For research use only. We do not sell to patients.
- Purity: 97.73%
- CAS No.: 2631667-06-4
- Molecular Weight:77.129 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Fusion-SIRPA-IGHG4 Fc
Human
CD47
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
FPIA_[PROTEIN]2-FC
-
Immobilized CD47 Protein, Human (HEK293, HY-P72917) can bind Maplirpacept. The EC50 for this effect is 74.77 ng/mL.
Chemical Information
-
CAS No. 2631667-06-4
-
Appearance Liquid
-
Molecular Weight 77.129 kDa
-
Color Colorless to light yellow
-
Synonyms
TTI-622; PF-07901801
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (255 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)